Isbn: 9798171207274 - the biotech ceo’s guide to your first fda meeting: 1 (cambase executive field guides) (2 Ergebnisse)

ISBN: 
Mit der Detailsuche verfeinern

Optimieren Sie Ihre Suche

  • Bücher (2)

  • Neu (2)

bis

Benutzerdefinierte Preisspanne (EUR)

bis

  • Sprache: Englisch

    Verlag: WENDE, 2026

    9798171207274

    Serie: Buch 1 von 1 - Cambase Executive Field Guides

    • Softcover

    Anbieter: PBShop.store UK, Fairford, GLOS, Vereinigtes KönigreichPBShop.store UK

    Verkäufer/-in mit 5 Sternen
    Verkäufer/-in kontaktieren

    Zustand: Neu

    EUR 18,91

    EUR 3,82 Versand 
    Versand von Vereinigtes Königreich nach USA

    Anzahl: Mehr als 20 verfügbar

    PAP. Zustand: New. New Book. Shipped from UK. Established seller since 2000.

  • Sprache: Englisch

    Verlag: Createspace Independent Publishing Platform Sep 2026, 2026

    9798171207274

    Serie: Buch 1 von 1 - Cambase Executive Field Guides

    • Softcover

    Anbieter: AHA-BUCH GmbH, Einbeck, DeutschlandAHA-BUCH GmbH

    Verkäufer/-in mit 5 Sternen
    Verkäufer/-in kontaktieren

    Zustand: Neu

    EUR 28,71

    EUR 35,00 Versand 
    Versand von Deutschland nach USA

    Anzahl: 2 verfügbar

    Taschenbuch. Zustand: Neu. Neuware - Your first FDA meeting could shape the future of your entire development program.But many biotech teams prepare for it as a regulatory event rather than a strategic decision point.They focus on the meeting request, briefing package, questions, and presentation-without first agreeing on what the company needs to learn, which decisions FDA's feedback must inform, or how the program will respond if the agency takes a different view.The Biotech CEO's Guide to Your First FDA Meeting offers a practical, executive-level framework for preparing more strategically.Written by Nilou Sarah Arden, PhD-a former FDA regulator and global biopharma regulatory leader-the guide helps biotech founders, CEOs, executives, and development teams look beyond the mechanics of the meeting and ask a more important question: What must this FDA interaction enable us to decide Inside, you will learn how to: - Define the decisions for which your company needs FDA input- Identify the most consequential uncertainties in your development plan- Prioritize questions that could materially change the program- Distinguish evidence, assumptions, beliefs, and unresolved uncertainty- Integrate CMC, nonclinical, clinical, and regulatory strategies- Recognize which questions should not be asked-or should not be asked yet- Build a briefing package that supports clear, decision-useful feedback- Prepare for disagreement, conditional advice, and unexpected responses- Decide which commitments should be made now and which can wait- Align the leadership team before entering the meetingThe guide also includes: - A one-page FDA meeting strategy- A five-minute strategic-readiness diagnostic- A CEO checklist for final preparation- A post-meeting framework for turning regulatory feedback into decisions, actions, and organizational learningThis is not a technical manual for writing an FDA briefing package. It is a field guide for leading the decisions around one.Whether your company is preparing for a pre-IND meeting, an initial regulatory interaction, or another consequential FDA milestone, this guide will help you connect regulatory strategy to the wider development pathway-including evidence, manufacturing, clinical planning, capital, sequencing, risk, and future options.Because a successful FDA meeting is not simply one that goes smoothly.It is one that helps the company make better decisions.Part of the Cambase Executive Field Guides series: practical intelligence for the decisions shaping the path from science to patients.…